Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Vivek Yadav, an engineering manager from ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

We recently published 10 Big Names Crushing the Market. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best-performing stocks on Friday. Recursion Pharmaceuticals soared by 8.31 percent ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

If Java is not working in Windows 11/10, these solutions may help you troubleshoot the issue. Although, due to the lack of NPAPI support, Java applets stopped working in Microsoft Edge, Google Chrome, ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Here are the most important concepts developers must know when they size Java arrays and deal ...

Before market open, Recursion disclosed in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC) that it was taking a series of measures to streamline its operations.

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...